BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32321318)

  • 21. Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.
    Radhakrishnan VS; Lokireddy P; Parihar M; Prakash PS; Menon H
    Cancer Rep (Hoboken); 2022 Jul; 5(7):e1590. PubMed ID: 34821081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for mantle cell lymphoma.
    Smolewski P; Witkowska M; Robak T
    Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
    Ferrer A; Marcé S; Bellosillo B; Villamor N; Bosch F; López-Guillermo A; Espinet B; Solé F; Montserrat E; Campo E; Colomer D
    Oncogene; 2004 Nov; 23(55):8941-9. PubMed ID: 15480431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
    Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
    Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
    Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
    Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
    Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
    Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
    Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
    J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
    Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
    Navarro Matilla B; García-Marco JA
    Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
    Agarwal R; Dawson MA; Dreyling M; Tam CS
    Leuk Lymphoma; 2018 Dec; 59(12):2769-2781. PubMed ID: 29912596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and emerging therapies in mantle cell lymphoma.
    Brett LK; Williams ME
    Curr Treat Options Oncol; 2013 Jun; 14(2):198-211. PubMed ID: 23512567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
    Papin A; Le Gouill S; Chiron D
    Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pathologic diagnosis of mantle cell lymphoma.
    Li S; Xu J; You MJ
    Histol Histopathol; 2021 Oct; 36(10):1037-1051. PubMed ID: 34114641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene mutations and actionable genetic lesions in mantle cell lymphoma.
    Ahmed M; Zhang L; Nomie K; Lam L; Wang M
    Oncotarget; 2016 Sep; 7(36):58638-58648. PubMed ID: 27449094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
    Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
    BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.